Payment overview · 2025
General Payments
$656.91
36 reported records · 12 companies
Healthcare provider profile · identity verified
Heidi Collins, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MANISTEE, MI · NPI 1336606078
Verified facts
What the public records show
CMS Open Payments records show Heidi Collins, NP received $656.91 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $265.76 | 40.5% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $77.80 | 11.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.50 | 9.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.73 | 9.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.36 | 4.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.73 | 4.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.54 | 4.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $24.05 | 3.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $21.13 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.99 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.40 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.92 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $656.91 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $201.34 | 11 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $77.80 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.50 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $64.42 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $30.36 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.94 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.73 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $19.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 79 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 284 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 283 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 259 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 241 | 63 |
| Lisinopril | Lisinopril | 241 | 62 |
| Gabapentin | Gabapentin | 235 | 49 |
| Simvastatin | Simvastatin | 145 | 38 |
| Montelukast Sodium | Montelukast Sodium | 144 | 27 |
| Metformin Hcl | Metformin Hcl | 130 | 31 |
| Losartan Potassium | Losartan Potassium | 127 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 25 |
| Amlodipine Besylate | Amlodipine Besylate | 122 | 29 |
| Alprazolam | Alprazolam | 106 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 20 |
| Prednisone | Prednisone | 103 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 35 |
| Sertraline Hcl | Sertraline Hcl | 84 | 14 |
| Famotidine | Famotidine | 80 | 13 |
| Eliquis | Apixaban | 79 | 14 |
| Pregabalin | Pregabalin | 76 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 16 |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 14 |
| Potassium Chloride | Potassium Chloride | 58 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 57 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 11 |
| Azithromycin | Azithromycin | 52 | 48 |
| Buspirone Hcl | Buspirone Hcl | 52 | 11 |
| Januvia | Sitagliptin Phosphate | 52 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 15 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 49 | suppressed |
| Atenolol | Atenolol | 48 | 12 |
| Trazodone Hcl | Trazodone Hcl | 48 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 47 | 14 |
| Tramadol Hcl | Tramadol Hcl | 46 | 19 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 11 |
| Ibuprofen | Ibuprofen | 39 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Carvedilol | Carvedilol | 37 | suppressed |
| Furosemide | Furosemide | 37 | 18 |
| Ozempic | Semaglutide | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 27 |
| Jardiance | Empagliflozin | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 23 |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Phenobarbital | Phenobarbital | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 17 |
| Cephalexin | Cephalexin | 20 | 18 |
| Naproxen | Naproxen | 20 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Norethindrone | Norethindrone | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Ritalin | Methylphenidate Hcl | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $656.91 · 36 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, FARXIGA, GARDASIL 9, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, SKYCLARYS, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VAXNEUVANCE, VRAYLAR, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error